TD Cowen raised the firm’s price target on McKesson to $563 from $508 and keeps an Outperform rating on the shares. The firm sees McKesson’s model providing solid visibility to double-digit adjusted EPS growth, achievable through multiple levers, and is well-positioned to benefit from secular tailwinds in biosimilar and specialty growth, the analyst tells investors in a research note. McKesson is a Best Idea for 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MCK:
- McKesson price target raised to $514 from $495 at JPMorgan
- McKesson price target raised to $508 from $499 at TD Cowen
- McKesson price target raised to $450 from $427 at Mizuho
- McKesson raises FY24 adjusted EPS view to $26.80-$27.40 from $26.55-$27.35
- McKesson reports Q2 adjusted EPS $6.23, consensus $6.11